- November 16, 2016
Startup Magenta Therapeutics licenses technologies from Harvard, MGH, and Boston Children’s that could transform treatment
- October 14, 2016
First annual Harvard FUSION symposium assembles leaders at the convergence of science and business
- April 27, 2016
Five research projects with commercial potential receive sustaining funding through Harvard’s Physical Sciences & Engineering Accelerator.
- August 19, 2015
Twelve advanced research projects aimed at developing new therapies and diagnostics receive support in 2015-16 from Harvard’s Blavatnik Biomedical Accelerator.
- March 04, 2015
NEWTON, Mass.--(BUSINESS WIRE)--Macrolide Pharmaceuticals, a new company with groundbreaking technology to develop novel antibiotics, completed a Series A financing of $22 million led by Novartis Venture Fund, Gurnet Point Capital, Roche Ventures, and SROne. The financing follows a worldwide license agreement between Harvard's Office of Technology Development and the company, providing exclusive rights to the technology.
Page 3 of 5